微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 35.63% | 37.96% | 5.32% | 100/158 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 33.83% | 41.39% | 20.68% | 103/158 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 28.03% | 4.53% | 3.72% | 120/158 | 50.33% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 27.03% | -2.61% | 4.65% | 122/158 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 25.83% | -10.61% | 7.94% | 126/158 | 14.78% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 23.93% | -21% | -10.78% | 126/158 | 31.79% | 艾力斯医药科技 | 96.74% | 行业排名> |
| 2024-12-31 | 26.82% | -17.36% | -3.37% | 125/158 | 51.59% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 27.75% | -16.4% | -3.94% | 120/158 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 28.89% | -15.98% | -4.6% | 120/158 | 32.96% | 百利天恒药业 | 97.99% | 行业排名> |
| 2024-03-31 | 30.29% | -16.16% | -6.68% | 116/158 | 51.47% | 百利天恒药业 | 98.92% | 行业排名> |
| 2023-12-31 | 32.45% | -12.69% | -2.25% | 112/158 | 51.32% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 33.2% | -12.09% | -3.46% | 110/158 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 34.39% | -8.93% | -4.8% | 111/158 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 36.12% | -5.9% | -2.82% | 107/158 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 37.17% | -9.55% | -1.57% | 108/158 | 53.52% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 37.76% | -11.88% | 0.02% | 102/158 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 37.76% | -14.54% | -1.64% | 106/158 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 38.39% | -17.69% | -6.58% | 98/158 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 41.09% | -9.63% | -4.11% | 97/158 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 42.85% | -7.54% | -3% | 84/158 | 46.49% | 艾力斯医药科技 | 99.41% | 行业排名> |
| 2021-06-30 | 44.18% | -8.74% | -5.27% | 85/158 | 46.97% | 艾力斯医药科技 | 98.7% | 行业排名> |
| 2021-03-31 | 46.64% | -13.78% | 2.56% | 72/158 | 53.79% | 艾力斯医药科技 | 99.4% | 行业排名> |
| 2020-12-31 | 45.47% | 18.1% | -1.89% | 92/158 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 46.35% | 18.5% | -4.26% | 78/158 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 48.41% | 22.53% | -10.5% | 76/158 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 54.09% | 22.49% | 40.48% | 53/158 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 38.5% | 9.86% | -1.56% | 100/158 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 39.12% | 3.73% | -1% | 79/158 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 39.51% | 2.06% | -10.53% | 82/158 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 44.16% | 12.18% | 26% | 67/158 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 35.05% | 32.79% | -7.06% | 102/158 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 37.71% | 58.63% | -2.6% | 77/158 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 38.71% | 74.8% | -1.65% | 74/158 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 39.36% | 86.92% | 49.14% | 72/158 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 26.39% | 36.37% | 11.04% | 109/158 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 23.77% | 21.76% | 7.33% | 89/158 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 22.15% | 15.85% | 5.16% | 95/158 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 21.06% | 8.65% | 8.81% | 81/158 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 19.35% | 55.34% | -0.86% | 107/158 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 19.52% | 81.01% | 2.11% | 77/158 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 19.12% | 78.86% | -1.37% | 85/158 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 19.38% | 245.36% | 55.57% | 73/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |